Clinical and metabolic outcomes in pregnant women at risk for gestational diabetes mellitus supplemented with myo-inositol: a secondary analysis from 3 RCTs


      Gestational diabetes mellitus is defined as carbohydrate intolerance that begins or is first recognized during pregnancy. Insulin sensitizing substances such as myo-inositol have been considered for the prevention of gestational diabetes mellitus and related complications.


      Because previous studies failed to show a clear reduction of gestational diabetes mellitus complications, the aim of this study was to evaluate clinical and metabolic outcomes in women who are at risk for gestational diabetes mellitus supplemented with myo-inositol since the first trimester.

      Study Design

      A secondary analysis of databases from 3 randomized, controlled trials (595 women enrolled) in which women who were at risk for gestational diabetes mellitus (a parent with type 2 diabetes mellitus, obese, or overweight) were supplemented with myo-inositol (4 g/d) throughout pregnancy. Main measures were the rate of adverse clinical outcomes: macrosomia (birthweight, ≥4000 g), large-for-gestational-age babies (fetal growth, ≥90 percentile), fetal growth restriction (fetal growth, ≤3 percentile), preterm birth (delivery before week 37 since the last menstruation), gestational hypertension, and gestational diabetes mellitus.


      A significant reduction was observed for preterm birth (10/291 [3.4%] vs 23/304 [7.6%]; P=.03), macrosomia (6/291 [2.1%] vs 16/304 [5.3%]; P=.04), Large-for-gestational-age babies (14/291 [4.8%] vs 27/304 [8.9%]; P=.04) with only a trend to significance for gestational hypertension (4/291 [1.4%] vs 12/304 [3.9%]; P=.07). Gestational diabetes mellitus diagnosis was also decreased when compared with the control group (32/291 [11.0%] vs 77/304 [25.3%]; P<.001). At univariate logistic regression analysis, myo-inositol treatment reduced the risk for preterm birth (odds ratio, 0.44; 95% confidence interval, 0.20–0.93), macrosomia (odds ratio, 0.38; 95% confidence interval, 0.14–0.98), and gestational diabetes mellitus diagnosis (odds ratio, 0.36; 95% confidence interval, 0.23–0.57).


      Myo-inositol treatment in early pregnancy is associated with a reduction in the rate of gestational diabetes mellitus and in the risk of preterm birth and macrosomia in women who are at risk for gestational diabetes mellitus.

      Key words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to American Journal of Obstetrics & Gynecology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • American College of Obstetricians and Gynecologists
        Gestational diabetes. ACOG Practice Bulletin no. 30.
        Obstet Gynecol. 2001; 98: 525-538
        • Farrar D.
        • Simmonds M.
        • Bryant M.
        • et al.
        Hyperglycaemia and risk of adverse perinatal outcomes: systematic reviews and meta-analysis.
        BMJ. 2016; 13 (354:i4694)
        • Metzger B.E.
        • Lowe L.P.
        • Dyer A.R.
        • et al.
        Hyperglycemia and adverse pregnancy outcomes.
        N Engl J Med. 2008; 358: 1991-2002
        • International Association of Diabetes and Pregnancy Study Groups Consensus Panel
        International association of diabetes and pregnancy study groups recommendations on the diagnosis and classification of hyperglycemia in pregnancy.
        Diabetes Care. 2010; 33: 676-682
        • Bain E.
        • Crane M.
        • Tieu J.
        • Han S.
        • Crowther C.A.
        • Middleton P.
        Diet and exercise interventions for preventing gestational diabetes mellitus.
        Cochrane Database Syst Rev. 2015; 4: CD010443
        • Ragozinska E.
        • D’Amico M.I.
        • Khan K.S.
        • et al.
        Development of composite outcomes for individual patient data (IPD) meta-analysis on the effects of diet and lifestyle in pregnancy: a Delphi survey.
        BJOG. 2016; 123: 190-198
        • Committee on Practice Bulletins–Obstetrics
        Practice Bulletin no.180: gestational diabetes mellitus.
        Obstet Gynecol. 2017; 130: e17-e37
        • Society of Maternal-Fetal Medicine Publication Committee
        SMFM statement: pharmacological treatment of gestational diabetes. SMFM Publications Committee.
        Am J Obstet Gynecol. 2018; 218: B2-B4
        • Langer O.
        • Conway D.L.
        • Berkus M.D.
        • Xenakis E.M.
        • Gonzales O.
        A comparison of glyburide and insulin in women with gestational diabetes mellitus.
        N Engl J Med. 2000; 343: 1134-1138
        • Zeng X.L.
        • Zhang Y.F.
        • Tian Q.
        • Xue Y.
        • An R.F.
        Effects of metformin on pregnancy outcomes in women with polycystic ovary syndrome.
        Medicine (Baltimore). 2016; 95: e4526
        • Feng L.
        • Lin X.F.
        • Wan Z.H.
        • Hu D.
        • Du Y.K.
        Efficacy of metformin on pregnancy complications in women with polycystic ovary syndrome: a meta-analysis.
        Gynecol Endocrinol. 2015; 31: 833-839
        • Zheng X.
        • Liu Z.
        • Lin Y.
        • Song J.
        • Zheng L.
        • Lin S.
        Relationship between myo-inositol supplementary and gestational diabetes mellitus: a meta-analysis.
        Medicine (Baltimore). 2015; 94: e1604
        • Guo X.
        • Guo S.
        • Miao Z.
        • Lin Z.
        • Zhang H.
        Myo-inositol lowers the risk of developing gestational diabetes mellitus in pregnancy: a systematic reviews and meta-analysis of randomized controlled trials with trial sequential analysis.
        J Diabetes Complications. 2018; 32: 342-348
        • Crawford T.J.
        • Crowther C.A.
        • Alsweiler J.
        • Brown J.
        Antenatal dietary supplementation with myo-inositol in women during pregnancy for preventing gestational diabetes.
        Cochrane Database Syst Rev. 2015; 12: CD011507
        • Larner J.
        • Brautigan D.L.
        • Thorner M.O.
        D-chiro inositol glycans in insulin signaling and insulin resistance.
        Mol Med. 2010; 16: 543-552
        • Coustan D.R.
        Can a dietary supplement prevent gestational diabetes mellitus?.
        Diabetes Care. 2013; 36: 777-779
        • Papaleo E.
        • Unfer V.
        • Baillargeon J.P.
        • et al.
        Myo-inositol in patients with polycystic ovary syndrome.
        Gynecol Endocrinol. 2007; 23: 700-703
        • Giordano D.
        • Corrado F.
        • Santamaria A.
        • et al.
        Effects of myo-inositol supplementation in postmenopausal women with metabolic syndrome: a perspective, randomized, placebo-controlled study.
        Menopause. 2011; 18: 102-104
        • Corrado F.
        • D’Anna R.
        • Di Vieste G.
        • et al.
        The effect of myoinositol supplementation on insulin resistance in patients with gestational diabetes.
        Diabet Med. 2011; 28: 972-975
        • D’Anna R.
        • Benedetto V.
        • Rizzo P.
        • et al.
        Myo-inositol may prevent gestational diabetes in PCOS women.
        Gynecol Endocrinol. 2012; 28: 440-442
        • D’Anna R.
        • Scilipoti A.
        • Giordano D.
        • et al.
        Myo-inositol supplementation and onset of gestational diabetes mellitus in pregnant women with a family history of type 2 diabetes.
        Diabetes Care. 2013; 36: 854-857
        • DʼAnna R.
        • Di Benedetto A.
        • Scilipoti A.
        • et al.
        Myo-inositol supplementation for prevention of gestational diabetes in obese pregnant women: a randomized controlled trial.
        Obstet Gynecol. 2015; 126: 310-315
        • Santamaria A.
        • Di Benedetto A.
        • Petrella E.
        • et al.
        Myo-inositol may prevent gestational diabetes onset in overweight women: a randomized, controlled trial.
        J Matern Fetal Neonatal Med. 2016; 29: 3234-3237
        • Bertino E.
        • Spada E.
        • Occhi L.
        • et al.
        Neonatal anthropometric charts: the Italian neonatal study compared with other European studies.
        J Pediatr Gastroenterol Nutr. 2010; 51: 353-361
        • Carlomagno G.
        • Unfer V.
        Inositol safety: clinical evidences.
        Eur Rev Med Pharmacol Sci. 2011; 15: 931-936
        • Matarrelli B.
        • Vitacolonna E.
        • D’Angelo M.
        • et al.
        Effect of dietary myo-inositol supplementation in pregnancy on the incidence of maternal gestational diabetes mellitus and fetal outcomes: a randomized, controlled trial.
        J Matern Fetal Neonatal Med. 2013; 26: 967-972
        • Farren M.
        • Daly N.
        • McKeating A.
        • Kinsley B.
        • Turner M.J.
        • Daly S.
        The prevention of gestational diabetes mellitus with antenatal oral inositol supplementation: a randomized, controlled trial.
        Diabetes Care. 2017; 40: 759-763
        • Syngelaki A.
        • Nicolaides K.H.
        • Balani J.
        • et al.
        Metformin versus placebo in obese pregnant women without diabetes mellitus.
        N Engl J Med. 2016; 374: 434-443
        • Croze M.L.
        • Soulage C.O.
        Potential role and therapeutic interest of myo-inositol in metabolic diseases.
        Biochimie. 2013; 95: 1811-1827
        • Viollet B.
        • Guigas B.
        • Sanz Garcia N.
        • Leclerc J.
        • Foretz M.
        • Andreelli F.
        Cellular and molecular mechanisms of metformin: an overview.
        Clin Sci (Lond). 2012; 122: 253-270